Proposed is a continuation of a productive, integrated, innovative Program Project in animal and laboratory models of breast cancer with actual and prospective clinical translatability. The goal is to address fundamental biological questions to advance our knowledge of metastasis and aberrant growth regulation and thereby improve all aspects of breast cancer prognostication, prediction of therapeutic benefit, and treatment. It is comprised of four projects, each led by a leader in the field, an Administrative Core to provide oversight and management, and a highly innovative RNAi Core to provide critical reagents as well as genetically engineered mouse models. Avoidance of duplication of effort, intellectual and material synergy, and orientation toward real clinical needs are hallmarks of this effort. The Projects and their Principal Investigators are: (1) TGF-beta, PI3K and HER2 pathways in breast cancer metastasis (Joan Massague, Ph.D.), (2) Role and regulation of Id1 during breast cancer metastasis initiation (Robert Benezra, Ph.D.), (3) Development of mechanism-based strategies for the treatment of advanced breast cancer with PI3K pathway inhibitors (Neal Rosen, Ph.D. and Sarat Chandarlapaty, M.D.)'and (4) RND1 - Mediated breast cancer suppression (Filippo G. Giancotti, M.D., Ph.D.). Administrative Core A is to be led by Larry Norton, M.D., who is also the Principal investigator of the Program. The Core B in RNAi Tools for Breast Cancer Research is to be led by Scott Lowe, Ph.D.

Public Health Relevance

Almost all cancer deaths are due to the growth of functionally disruptive lesions in metastatic sites. This proposal uses animal and laboratory models to dissect an interlinking network of molecular signals and pathways to lead to better prognostic and predictive clinical tests and more effective, less toxic treatments that target such aberrations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (M1))
Program Officer
Mohla, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Will, Marie; Qin, Alice Can Ran; Toy, Weiyi et al. (2014) Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 4:334-47
Bokacheva, Louisa; Ackerstaff, Ellen; LeKaye, H Carl et al. (2014) High-field small animal magnetic resonance oncology studies. Phys Med Biol 59:R65-R127
Giancotti, Filippo G (2014) Deregulation of cell signaling in cancer. FEBS Lett 588:2558-70
Brader, Peter; Serganova, Inna; Blasberg, Ronald G (2013) Noninvasive molecular imaging using reporter genes. J Nucl Med 54:167-72
Stankic, Marko; Pavlovic, Svetlana; Chin, Yvette et al. (2013) TGF-*-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep 5:1228-42
Lockwood, William W; Chandel, Sahiba K; Stewart, Greg L et al. (2013) The novel ubiquitin ligase complex, SCF(Fbxw4), interacts with the COP9 signalosome in an F-box dependent manner, is mutated, lost and under-expressed in human cancers. PLoS One 8:e63610
Vanharanta, Sakari; Massagué, Joan (2013) Origins of metastatic traits. Cancer Cell 24:410-21
Zhang, Xiang H-F; Jin, Xin; Malladi, Srinivas et al. (2013) Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154:1060-73
Kass, Elizabeth M; Helgadottir, Hildur R; Chen, Chun-Chin et al. (2013) Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase. Proc Natl Acad Sci U S A 110:5564-9
Beverly, Levi J; Lockwood, William W; Shah, Parag P et al. (2012) Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci U S A 109:E119-26

Showing the most recent 10 out of 69 publications